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Abstract
Introduction: Osteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing
bisphosphonates intravenously due to malignant diseases. Albeit far less frequently, osteonecrosis of the jaw has
also been reported to occur due to the oral administration of nitrogen-containing bisphosphonates due to
osteoporosis. Annual infusions of zoledronic acid have been recommended in order to improve patient
compliance, to optimize therapeutic effects and to minimize side effects. To date, osteonecrosis of the jaw has not
been linked to the annual administration of bisphosphonates.
Case presentation: We report the case of a 65-year-old Caucasian woman suffering from osteoporosis who
developed early stage osteonecrosis of the jaw in two locations, with chronic infections, after two months of oral
bisphosphonate treatment and three annual administrations of zoledronic acid. Our patient was treated by
fluorescence-guided resection of the necrotic jaw bone areas; local inflammation was treated by removal of a
wisdom tooth and repeat root resections. Histopathology revealed typical hallmarks of osteonecrosis of the jaw.
Conclusion: Osteonecrosis of the jaw may occur as a consequence of annual administrations of zoledronic acid. It
is conceivable that, due to the pharmacological properties of bisphosphonates, a jaw bone that encounters
frequent local inflammations is more likely to develop osteonecrosis.
Introduction
Osteoporosis can be managed effectively with bisphospho-
nates. These antiresorptive drugs significantly prevent
skeletal complications, particularly fractures. Side effects
of bisphosphonate therapy are rare but potentially serious
as exemplified in the bisphosphonate-related osteonecrosis
of the jaw (ONJ). First described in 2003, [1] ONJ is
defined by the presence of transmucosal or transcutaneous
jawbone exposure for at least eight weeks, a history of
bisphosphonate administration, and the absence of any
history of irradiation to the head and neck region [2].
Retrospective studies have identified a prevalence of up to
19% in patients that have received intravenous bis-
phosphonate applications due to cancer with bone metas-
tasis [3]. In contrast ONJ is rare in osteoporosis patients
receiving oral bisphosphonates, where the prevalence
approximates 0.1% [4] (equivalent to 7.8% of all cases of
bisphosphonate-related ONJ [5]).
Recent studies have revealed that annual intravenous
administration of zoledronic acid decreases bone turn-
over and increases bone density in postmenopausal
women with osteoporosis, thereby reducing the risk of
vertebral, hip and other fractures. This bisphosphonate
regime is generally well tolerated and has a favorable
safety profile. Indeed, to date, no reports of bisphospho-
nate-related ONJ have emerged [6].
This case described in this report suggests that annual
infusions of zoledronic acid may lead to bisphospho-
nate-related ONJ and offers further insights into the
pathomechanisms of ONJ.
Case presentation
A 65-year-old female Caucasian patient, suffering from
intraoral purulent discharge in her left mandibular angle
and the front of her left upper jaw, was referred to our
hospital by her dentist. Her medical history revealed that
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she had suffered from postmenopausal osteoporosis,
which was initially treated with two months of alendronate
(70 mg once weekly) administered orally, followed by
three annual infusions of zoledronic acid (5 mg intrave-
nously). In addition, our patient was allergic to penicillin
and was treated for diabetes mellitus type II with
metformin.
Intraoral examination revealed the presence of a fis-
tula formation in her left mandibular angle in region 38
(Figure 1a) communicating with a retained left third
molar. There was also a fistula formation in her upper
jaw (region 22/23) communicating with her upper left
lateral incisor and canine (teeth 22 and 23), which
showed signs of chronic endodontic infections and had
received endodontic and surgical treatment (root resec-
tion) in the past (Figure 2a). Both sites were marked by
a purulent discharge on compression which was accom-
panied by mild to moderate pain on palpation. A
panoramic radiograph and cone beam computed tomo-
graphy identified radiolucent areas at the resected apices
of teeth 22 and 23 as well as the region surrounding her
left lower wisdom tooth (Figure 1b and 2b).
A fluorescence-guided removal of necrotic bone parts
in her left mandibular angle was performed as previously
described [7] and her left third molar was removed
(Figure 1c-f). In addition, the upper jaw necrotic bone
was resected under fluorescence-guidance and a root-
resection of her lateral incisor and canine was carried out
under general anesthesia (Figure 2c-g). Furthermore, her
right third molar was removed. After the procedure, our
patient received an intravenous antibiotic treatment (clin-
damycin 600 mg, three times daily) and was discharged
five days later. The antibiotic was continued for 10 days
at the same dose. During the follow-up there was no sign
of infection and complete mucosal closure was achieved
at all sites (Figure 1g and 2i).
Histological evaluation revealed the typical hallmarks
of an early ONJ lesion, including areas of necrotic bone
coinciding with signs of infections as well as areas with
increased bone turnover (Figure 2h).
Conclusion
Osteoporosis, a health threat of major public concern, is
effectively managed with the oral administration of
bisphosphonates. They significantly prevent skeletal com-
plications, particularly fractures [8]. Although bisphospho-
nates are generally well tolerated and side effects are rare,
bisphosphonate exposure has been linked to ONJ, which
in recent years has been highlighted to potentially consti-
tute a problem of serious clinical importance. ONJ is most
prevalent in patients suffering from metastatic bone dis-
ease, who have received nitrogen-containing bisphospho-
nates intravenously. Cases of ONJ due to osteoporosis
bisphosphonate therapy are less frequent [5].
Recent studies have proclaimed that the annual
intravenous administration of zoledronic acid for
osteoporosis therapy is safe, particularly regarding the
development of ONJ [6]. In the HORIZON study,
which encompassed 3876 patients, 76% (2950 patients)
received three annual infusions of zoledronic acid and
Figure 1 a) Intraoral examination of her left upper jaw with
fistula formation and pus on palpation in region 23; b) dental
X-ray examination with gutta-percha pin in the fistula; c)
intraoperative view with bony defect in region 23; d)
fluorescence optic view with loss of fluorescence in region; e)
bone cylinder region 23 with f) a mild fluorescence in the
superficial areas and almost complete loss of fluorescence in
deeper areas; g) corresponding clinical picture of the bone
cylinder; h) histological examination of a representative biopsy
with necrotic bone.
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completed the follow-up [6]. Whilst no cases of ONJ
were initially reported, database searches and expert
adjudications identified two potential cases of ONJ
(one in the placebo group and one in the zoledronic
acid group). However, the reliability of ONJ diagnosis
based on database searches or questionnaires (as
frequently performed in retrospective studies) is ques-
tionable. Indeed, a recent study has suggested that the
study design is of crucial importance and any retro-
spective study results in a significant underestimation
of ONJ prevalence. It is certainly a drawback that the
definition and diagnosis of bisphosphonate-related
Figure 2 a) intraoral examination of her left lower jaw with fistula formation and pus on palpation in region 38; b) panoramic
radiograph with mixed radiopaque and radiolucent areas surrounding the retained wisdom tooth 38; c) intraoperative situs after
wisdom tooth removal; d) corresponding fluorescence picture with loss of fluorescence in the lingual aspects of region 38; e)
intraoperative situs after removal of necrotic bone parts; f) corresponding fluorescence picture with markedly enhanced fluorescence
in the lingual aspects of region 38; g) intraoral examination eight weeks postoperatively with complete mucosal closure and without
fistula formation; h) panoramic radiograph after removal of the wisdom tooth 38 and necrotic bone parts; i) intraoral examination
eight weeks postoperatively with complete mucosal closure and without fistula formation.
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ONJ currently excludes histopathological evidence and
relies predominantly on the medical history [2]. Since
the inclusion of stadium 0 (no exposed bone, but
unspecific symptoms of infection) in the staging of
bisphosphonate-related ONJ [9], the diagnosis of early
stages has to be considered to be vague, at best. Given
that patients in stage 0 and I may only have unspecific
symptoms (if any), it is of paramount importance to
include detailed oral examinations in any diagnosis of
bisphosphonate-related ONJ.
Despite the large number of patients included in the
HORIZON trial, the follow-up period was relatively short
(limited to 36 months following the commencement of
the study and 12 months after the third and last infusion
of zoledronic acid) [6]. In light of the fact that bispho-
sphonates have an extremely long half-life in bone,
patients will not only continue to benefit but also remain
at risk of developing bisphosphonate-related ONJ for an
extended period, especially when an odontogenic infec-
tion is present or dentoalveolar surgical procedures are
performed. Bisphosphonates bind to bone at around
neutral pH and are released in acidic milieus. This phy-
siologic mechanism takes place in the resorption lacunas
during bone resorption, a feature that has been linked to
the pathogenesis of ONJ [10]. Acidic conditions are com-
mon during infections and the jawbone is frequently sub-
jected to acute and chronic infections. Indeed, in older
patients (aged 65 or above) the prevalence of moderate to
severe infections (periodontitis) exceeds 90%. The result-
ing change in pH may lead to a localized release and acti-
vation of bisphosphonates, which may trigger the onset
of ONJ [10].
Detailed regular intraoral examinations are therefore
imperative in order to treat dentoalveolar inflammations
and detect early stages of ONJ lesions. If diagnosed
timely, the outcomes of ONJ therapy are good; surgical
approaches or conservative treatment strategies result in
favorable outcomes in over 80% or 60%, respectively [7].
All patients receiving yearly infusions of bisphospho-
nates for osteoporosis should be adequately informed con-
cerning the risk of ONJ. In addition, oral examinations
and (where appropriate) preventive measures are called
for in order to eliminate local inflammations–thereby
minimizing the risk of ONJ manifestation.
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